- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05698017
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA
January 24, 2023 updated by: Cytora Ltd.
Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
Purpose of this phase 1/2a study is to assess the safety and efficacy of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA) .
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel Aviv, Israel
- Recruiting
- Tel-Aviv Sourasky Medical Center (Ichilov)
-
Contact:
- Adi Ezra, MHA
- Phone Number: 972-52-4266940
- Email: adil@tlvmc.gov.il
-
Principal Investigator:
- Vered Livneh, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient was diagnosed with probable MSA-C (cerebellar) or MSA-P (parkinsonian) variant within 60 months of symptom onset (excluding impotence)
- Subject can ambulate without the assistance of another person, defined as the ability to take at least 10 steps. Use of assistive devices is allowed
- Patient cognitive state permits him to sign informed consent, according to the PI's clinical judgement, and MoCA >= 24
Exclusion Criteria:
- Pregnant women and women before menopause
- Participants with a clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the treatment or affect the treatment outcome.
- Patients with thrombocytopenia, other bleeding diathesis or taking anticoagulant therapy (not including Aspirin up to 100mg per day)
- Patients with known hypersensitivities to Plasmalyte, Gadolinium, Penicillin, and with general hypersensitivity to antibiotics
- Patients who fulfill the criteria of Parkinson's Disease
- History of electroconvulsive therapy
- History of brain surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Low dose hOMSC300
Single IT administration of low dose hOMSC300
|
Human Oral Mucosa Stem Cells
|
Active Comparator: High dose hOMSC300
Single IT administration of high dose hOMSC300
|
Human Oral Mucosa Stem Cells
|
Other: Sham Procedure
Lumbar puncture only
|
Lumbar Puncture Only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment related SAEs per dose group
Time Frame: 18 months
|
18 months
|
Treatment related adverse events per dose group
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinically significant motor and behavioral change from baseline
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 7, 2022
Primary Completion (Anticipated)
February 19, 2026
Study Completion (Anticipated)
February 19, 2026
Study Registration Dates
First Submitted
January 16, 2023
First Submitted That Met QC Criteria
January 24, 2023
First Posted (Estimate)
January 26, 2023
Study Record Updates
Last Update Posted (Estimate)
January 26, 2023
Last Update Submitted That Met QC Criteria
January 24, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Pathological Conditions, Anatomical
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Hypotension
- Atrophy
- Multiple System Atrophy
- Shy-Drager Syndrome
Other Study ID Numbers
- Cyt MSA hOMSC300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple System Atrophy
-
Brigham and Women's HospitalBiohaven Pharmaceuticals, Inc.CompletedMultiple System Atrophy | Multiple System Atrophy, Parkinson Variant (Disorder) | Multiple System Atrophy, Cerebellar Variant | Multiple System Atrophy (MSA) With Orthostatic HypotensionUnited States
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)CompletedMultiple System Atrophy - Parkinsonian Subtype (MSA-P) | Multiple System Atrophy - Cerebellar Subtype (MSA-C)United States
-
Dana HorakovaUnknownMultiple Sclerosis | Cognitive Change | Atrophy Brain | Atrophy; Spinal CordCzechia
-
Samsung Medical CenterUnknownMultiple System Atrophy, Cerebellar Variant (Disorder)Korea, Republic of
-
Ono Pharmaceutical Co. LtdRecruitingMultiple System Atrophy (MSA)United States
-
Biohaven Pharmaceuticals, Inc.No longer availableMultiple System Atrophy (MSA)United States
-
University Hospital, BordeauxCompleted
-
AstraZenecaCompletedMultiple System Atrophy, MSAUnited States, Finland, Austria, France, Sweden, United Kingdom, Italy
-
University of Texas Southwestern Medical CenterRecruiting
-
Indonesia UniversityRecruitingParkinsonism | Multiple System Atrophy | Multiple System Atrophy, Parkinson VariantIndonesia